RecruitingAtopic Dermatitis
Molecular Signatures of Cutaneous Dupilumab Response
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Sponsor: University of California, San Francisco
You may qualify if…
- ✓ 1. 18 years of age or older
- ✓ 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
You may not qualify if…
- ✕ 1. Known pregnancy
- ✕ 2. Known immunodeficiencies
- ✕ 3. Known parasitic infection -
Where it's recruiting
California
San Francisco
Source: ClinicalTrials.gov · NCT05858619 · last updated 2026-06-04